var data={"title":"Factor IX, human plasma-derived: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Factor IX, human plasma-derived: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/541150?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=factor-ix-human-plasma-derived-drug-information\" class=\"drug drug_general\">see &quot;Factor IX, human plasma-derived: Drug information&quot;</a> and <a href=\"topic.htm?path=factor-ix-human-plasma-derived-patient-drug-information\" class=\"drug drug_patient\">see &quot;Factor IX, human plasma-derived: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264034\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>AlphaNine SD;</li>\n      <li>Mononine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264035\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Immunine VH</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23324420\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihemophilic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Blood Product Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23324583\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Contains <b>nondetectable levels of factors II, VII, and X</b>; therefore, <b>NOT INDICATED</b> for replacement therapy of any other clotting factor besides factor IX or for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), for hemophilia A patients with factor VIII inhibitors, or for patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Control or prevention of bleeding in patients with factor IX deficiency (hemophilia B or Christmas disease):</b> IV: Dosage  is expressed in units of factor IX activity and must be individualized based on formulation, severity of factor IX deficiency, extent and location of bleed, and clinical situation of patient.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Formula for units required to raise blood level: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mononine:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Number of Factor IX Units  Required = body weight (in kg) x desired Factor IX level increase (% or units/dL) x 1 unit/kg </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">For example, for a 100% level in a 3 kg patient who has an actual level of 20%: Number of Factor IX Units needed = 3 kg x 80% x 1 unit/kg = 240 units </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent IV: Desired Factor IX level, dosing interval, and duration based on hemorrhage type: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Minor hemorrhage (eg, bruising, cuts/scrapes, uncomplicated joint hemorrhage)/Prophylaxis: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Desired factor IX levels (% or units/dL): 15 to 25 </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Frequency of dosing: Every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Duration of treatment: 1 to 2 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Major trauma or surgery: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Desired factor IX levels (% or units/dL): 25 to 50 </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Frequency of dosing: Every 18 to 30 hours; interval dependent upon half-life and measured factor IX levels </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Duration of treatment: Up to 10 days depending on nature of insult </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23324425\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=factor-ix-human-plasma-derived-drug-information\" class=\"drug drug_general\">see &quot;Factor IX, human plasma-derived: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>NOTE:</b> Contains <b>nondetectable levels of factors II, VII, and X</b>; therefore, <b>NOT INDICATED</b> for replacement therapy of any other clotting factor besides factor IX or for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), for hemophilia A patients with factor VIII inhibitors, or for patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Control or prevention of bleeding in patients with factor IX deficiency (hemophilia B or Christmas disease):</b> Infants, Children, and Adolescents:  IV: Dosage is expressed in units of factor IX activity and must be individualized based on formulation, severity of factor IX deficiency, extent and location of bleed, and clinical situation of patient. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Formula for units required to raise blood level: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Number of Factor IX Units Required = body weight (in kg) x desired Factor IX level increase (% or units/dL) x 1 unit/kg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For example, for a 100% level in a 25 kg patient who has an actual level of 20%: Number of Factor IX Units needed = 25 kg x 80% x 1 unit/kg = 2000 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Manufacturer's labeling: </i>AlphaNine SD, Mononine: Infants, Children, and Adolescents: Intermittent IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Desired Factor IX Level, Dosing Interval and Duration based on Hemorrhage Type: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Minor hemorrhage (eg, bruising, cuts/scrapes, uncomplicated joint hemorrhage): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Desired factor IX levels (% or units/dL): 15 to 30 </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Frequency of dosing: Every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Duration of treatment: 1 to 2 days </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate hemorrhage (eg, epistaxis, oropharyngeal bleeds, dental extractions, hematuria):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Desired factor IX levels (% or units/dL): 25 to 50</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Frequency of dosing: Every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Duration of treatment: 2 to 7 days  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Major hemorrhage [eg, joint and muscle (especially large muscles) hemorrhage, intracranial or intraperitoneal hemorrhage], major trauma, or surgical prophylaxis: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Desired factor IX levels (% or units/dL): 50 to 100 (depending on the clinical situation, desired Factor IX level may be reduced following active treatment period for hemorrhage or &gt;48 hours postop) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Frequency of dosing: Every 12 to 24 hours (AlphaNine SD) or 18 to 30 hours (Mononine), interval dependent upon product used, half-life, and measured factor IX levels (after 3 to 5 days, maintain at least 20% activity) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Duration of treatment: 7 to 10 days, depending upon nature of insult </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Alternate dosing:</i> <b>Note:</b> The following recommendations reflect general dosing requirements; may vary from those found within prescribing information or practitioner preference: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prophylaxis, primary: Infants, Children, and Adolescents: IV: 15 to 30 units/kg twice weekly (WFH guidelines [Srivastava 2013] [Utrecht protocol]) <b>or</b> 25 to 40 units/kg twice weekly [WFH guidelines (Srivastava 2013) (Malm&ouml; protocol)] <b>or</b> 40 to 100 units/kg 2 to 3 times weekly (National Hemophilia Foundation, MASAC recommendation 2007); however, the optimum regimen has yet to be defined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemorrhage, treatment (when no significant resource constraints exist) [WFH guidelines (Srivastava 2013)]: <b>Note:</b> Factor IX level may either be expressed as units/dL or as %. Dosing frequency most commonly corresponds to the half-life of factor IX but should be determined based on an assessment of factor IX levels before the next dose. Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent IV: Desired Factor IX Level to Maintain and Duration Based on Site of Hemorrhage/Clinical Situation:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Joint: 40 to 60 units/dL for 1-2 days, may be longer if response is inadequate </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Superficial muscle (no neurovascular compromise): 40 to 60 units/dL for 2-3 days, sometimes longer if response is inadequate </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss: Initial: 60 to 80 units/dL for 1 to 2 days; Maintenance: 30 to 60 units/dL for 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CNS/head: Initial: 60 to 80 units/dL for 1 to 7 days; Maintenance: 30 units/dL for 8 to 21 days </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Throat and neck: Initial: 60 to 80 units/dL for 1 to 7 days; Maintenance: 30 units/dL for 8 to 14 days </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Gastrointestinal: Initial: 60 to 80 units/dL for 7 to 14 days; Maintenance: 30 units/dL (duration not specified) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Renal: 40 units/dL for 3 to 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Deep laceration: 40 units/dL for 5 to 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Surgery (major): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Preop: 60 to 80 units/dL </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Postop: 40 to 60 units/dL for 1 to 3 days, then 30 to 50 units/dL for 4 to 6 days, then 20 to 40 units/dL for 7 to 14 days </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Surgery (minor): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Preop: 50 to 80 units/dL</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Postop: 30 to 80 units/dL for 1 to 5 days depending on procedure type</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Very limited data available; only data with Mononine product available: <b>Note:</b> Used for patients who require prolonged periods of treatment (eg, intracranial hemorrhage or surgery) to avoid peaks and troughs associated with intermittent infusions [Batorova 2002; Hoots 2003; Morfini 2008; Poon 2012; WFH guidelines (Srivastava 2013)]: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Following initial bolus to achieve the desired factor IX level: Initial dosing: 4 to 6 units/kg/hour; adjust dose based on frequent factor IX assays and calculation of factor IX clearance at steady-state using the following equations: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Factor IX clearance (mL/kg/hour) = (current infusion rate in units/kg/hour)/(plasma Factor IX level in units/<b>mL)</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">New infusion rate (units/kg/hour) = (factor IX clearance in mL/kg/hour) x (desired plasma level in units/<b>mL</b>) </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">The median reported dose in post-operative patients (7-85 years) was 3.84 units/kg/hour (range: 1.74 to 7.3 units/kg/hour) (Hoots 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Control or prevention of bleeding in patients with factor IX deficiency (hemophilia B or Christmas disease):</b> IV: AlphaNine SD, Mononine: Dosage is expressed in units of factor IX activity; dosing must be individualized based on severity of factor IX deficiency, extent and location of bleeding, and clinical status of patient. Refer to product information for specific manufacturer recommended dosing. Alternatively, the WFH has recommended general dosing for factor IX products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Formula for units required to raise blood level:</i> <b>Note</b>: If patient has severe hemophilia (ie, baseline factor IX level is or presumed to be &lt;1%), then may just use &ldquo;desired factor IX level&rdquo; instead of &ldquo;desired factor IX level increase&rdquo;.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Number of factor IX units required = patient weight (in kg) x desired factor IX level increase (as % or units/dL) x 1 unit/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">For example, to attain an 80% level in a 70 kg patient who has a baseline level of 20%: Number of factor IX units needed = 70 kg x 60% x 1 unit/kg = 4,200 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>WFH guidelines (Srivastava 2013):</i> <b>Note:</b> The following recommendations may vary from those found within prescribing information or practitioner preference.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prophylaxis: IV: 15 to 30 units/kg twice weekly [WFH guidelines (Srivastava 2013) (Utrecht protocol)] <b>or</b> 25 to 40 units/kg twice weekly [WFH guidelines (Srivastava 2013) (Malm&#1255; protocol)] <b>or</b> 40 to 100 units/kg administered 2 to 3 times weekly (National Hemophilia Foundation, MASAC recommendation 2007); optimum regimen has yet to be defined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent IV: 2013 World Federation of Hemophilia Treatment Recommendations (When No Significant Resource Constraint Exists): <b>Note:</b> Factor IX level may either be expressed as units/dL or as %. Dosing frequency most commonly corresponds to the half-life of factor IX but should be determined based on an assessment of factor IX levels before the next dose. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Desired  Factor IX Level to Maintain and Duration Based on Site of Hemorrhage/Clinical Situation:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Joint: 40 to 60 units/dL for 1 to 2 days, may be longer if response is inadequate </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Superficial muscle (no neurovascular compromise): 40 to 60 units/dL for 2 to 3 days, sometimes longer if response is inadequate </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss: Initial: 60 to 80 units/dL for 1 to 2 days; Maintenance: 30 to 60 units/dL for 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CNS/head: Initial: 60 to 80 units/dL for 1 to 7 days; Maintenance: 30 units/dL for 8 to 21 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Throat and neck: Initial: 60 to 80 units/dL for 1 to 7 days; Maintenance: 30 units/dL for 8 to 14 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Gastrointestinal: Initial: 60 to 80 units/dL for 7 to 14 days; Maintenance: 30 units/dL (duration not specified) </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Renal: 40 units/dL for 3 to 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Deep laceration: 40 units/dL for 5 to 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Surgery (major): </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Preop: 60 to 80 units/dL </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Postop: 40 to 60 units/dL for 1 to 3 days, then 30 to 50 units/dL for 4 to 6 days, then 20 to 40 units/dL for 7 to 14 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Surgery (minor): </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Preop: 50 to 80 units/dL</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Postop: 30 to 80 units/dL for 1 to 5 days depending on procedure type</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous IV infusion: <b>Note:</b> For patients who require prolonged periods of treatment (eg, intracranial hemorrhage or surgery) to avoid peaks and troughs associated with intermittent infusion [Batorova 2002; Poon 2012; Rickard 1995; WFH guidelines (Srivastava 2013)]: Following initial bolus to achieve the desired factor IX level: Initiate 4 to 6 units/kg/hour; adjust dose based on frequent factor assays and calculation of factor IX clearance at steady-state using the following equations:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Factor IX clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) divided by (plasma level in units/<b>mL</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">New infusion rate (units/kg/hour) = (factor IX clearance in mL/kg/hour) x (desired plasma level in units/<b>mL</b>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321198\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AlphaNine SD: 500 units (1 ea) [contains heparin, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AlphaNine SD: 500 units (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AlphaNine SD: 1000 units (1 ea) [contains heparin, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AlphaNine SD: 1000 units (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AlphaNine SD: 1500 units (1 ea) [contains heparin, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mononine: 250 units (1 ea [DSC]); 500 units (1 ea [DSC]); 1000 units (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264037\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573583\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=factor-ix-human-plasma-derived-drug-information\" class=\"drug drug_general\">see &quot;Factor IX, human plasma-derived: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Strengths expressed with approximate values. Consult individual vial labels for exact potency within each vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23324426\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Solution should be infused at room temperature. With patients who have had allergic reactions during factor IX infusion, administration of hydrocortisone prior to infusion may be necessary [WFH guidelines (Srivastava 2013)]. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV bolus: Should be infused <b>slowly over several minutes</b>: Rate of administration should be determined by the response and comfort of the patient. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AlphaNine SD: Administer IV at a rate not exceeding 10 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mononine: Administer IV at a rate of ~2 mL/minute. Administration rates of up to 225 <b>units</b>/minute have been regularly tolerated without incident (when reconstituted as directed to ~100 units/mL).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">WFH recommendations  (Srivastava 2013): Infuse at a rate determined by age: Young children: 100 <b>units</b>/minute; Adults: 3 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous IV infusion: In an open-label, multicenter trial (age range: 7 to 85 years), Mononine was administered as a continuous infusion either as the reconstituted solution or further diluted. The preparation of solution for infusion is dependent upon prescriber discretion and should be replaced every 12 hours (Hoots 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265579\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">When stored at refrigerator temperature, 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F), factor IX is stable for the period indicated by the expiration date on its label. Avoid freezing which may damage container for the diluent. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AlphaNine SD: May also be stored at room temperature not to exceed 30&deg;C (86&deg;F) for up to 1 month. Reconstituted solution should be used within 3 hours of preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mononine: May also be stored at room temperature not to exceed 25&deg;C (77&deg;F) for up to 1 month. Reconstituted solution should be at room temperature and used within 3 hours of preparation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23324421\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AlphaNine SD: Prevention and control of bleeding in factor IX deficiency (hemophilia B or Christmas disease) (FDA approved in ages &ge;16 years and  adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mononine: Prevention and control of bleeding in factor IX deficiency (hemophilia B or Christmas disease) (FDA approved in all ages)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>NOTE:</b> Contains <b>nondetectable levels of factors II, VII, and X</b>; therefore, <b>NOT INDICATED</b> for replacement therapy of any other clotting factor besides factor IX or for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), for hemophilia A patients with factor VIII inhibitors, or for patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264032\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Factor IX may be confused with Factor IX Complex </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265559\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Flushing, thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Burning sensation (in jaw/skull), chills, headache, lethargy, paresthesia, rigors </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin photosensitivity, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Disseminated intravascular coagulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Discomfort at injection site (stinging, burning), injection site reaction, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Neck tightness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Allergic rhinitis, asthma, laryngeal edema, pulmonary disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever (including transient fever following rapid administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare, but important or life-threatening: Cerebral hemorrhage (intrathalamic [Douvas, 2004]), cyanosis, decreased therapeutic response, factor IX inhibitor development, hypotension, myocardial infarction (high doses), pulmonary embolism (high doses), superior vena cava syndrome (neonates [Douvas, 2004])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264049\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AlphaNine SD: There are no contraindications listed in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mononine: Hypersensitivity to mouse protein</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264050\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: The development of factor IX antibodies (or inhibitors) has been reported with factor IX therapy (usually occurs within the first 10 to 20 exposure days); the risk of severe hypersensitivity reactions occurring may be greater in these patients. When clinical response is suboptimal, the patient has reached a specified number of exposure days, or patient is to undergo surgical procedure, screen for inhibitors. Patients with severe hemophilia compared to those with mild or moderate hemophilia are more likely to develop inhibitors (WFH [Srivastava  2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity and anaphylactic reactions have been reported with use. Delayed reactions (up to 20 days after infusion) in previously untreated patients may also occur. Due to potential for allergic reactions, the initial ~10 to 20 administrations should be performed under appropriate medical supervision. Hypersensitivity reactions may be associated with factor IX inhibitor development; patients experiencing allergic reactions should be evaluated for factor IX inhibitors (WFH [Srivastava  2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic events: Observe closely for signs or symptoms of intravascular coagulation or thrombosis; risk is generally associated with the use of factor IX complex concentrates (containing therapeutic amounts of additional factors); however, potential risk exists with use of factor IX products (containing only factor IX). Use with caution when administering to patients with liver disease, postoperatively, neonates, or patients at risk of thromboembolic phenomena, disseminated intravascular coagulation or patients with signs of fibrinolysis due to the potential risk of thromboembolic complications. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with extreme caution in patients with hepatic impairment due to the risk of thromboembolic complications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma. Despite purification methods (AlphaNine SD - solvent detergent treated/virus filtered; Mononine - virus filtered); products may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens).  Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Contains <b>nondetectable levels of factors II, VII, and X.</b> Therefore, <b>NOT INDICATED</b> for replacement therapy of any other clotting factor besides factor IX. In addition, factor IX concentrate is <b>NOT INDICATED </b>for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), hemophilia A patients with factor VIII inhibitors, or patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Clinical response: Response to factor IX administration may vary. If bleeding is not controlled with the recommended dose, determine plasma level of factor IX and follow with a sufficient dose to achieve satisfactory clinical response. If plasma levels of factor IX fail to increase as expected or bleeding continues, suspect the presence of an inhibitor; test as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune tolerance induction: Safety and efficacy have not been established in immune tolerance induction with factor IX products. Nephrotic syndrome has occurred following immune tolerance induction in patients with factor IX inhibitors and a history of allergic reactions to therapy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25820027\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use with caution when administering to neonates; the safety and efficacy of continuous infusion administration has not been established; thrombotic events have been reported in patients receiving continuous infusion of recombinant Factor IX through a central venous catheter, including life-threatening superior vena cava syndrome in neonates.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16369064\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16369062\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=93440&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264047\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264048\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Factor IX concentrations do not change significantly in pregnant women with coagulation disorders and women with factor IX deficiency may be at increased risk of postpartum hemorrhage. Pregnant women should have clotting factors monitored, particularly at 28 and 34 weeks gestation and prior to invasive procedures. Prophylaxis may be needed if factor IX concentrations are &lt;50 units/mL at term and treatment should continue for 3 to 5 days postpartum depending on route of delivery. Because parvovirus infection may cause hydrops fetalis or fetal death, a recombinant product is preferred if prophylaxis or treatment is needed. The neonate may also be at an increased risk of bleeding following delivery and should be tested for the coagulation disorder (Chi, 2012; Kadir, 2009; Lee, 2006). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23324427\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Factor IX levels [measure 15 minutes after infusion to verify calculated doses [WFH guidelines (Srivastava 2013)], aPTT, BP, HR, signs of hypersensitivity reactions; screen for factor IX inhibitors if the patient experiences hypersensitivity reaction or when patient is to undergo surgery, if suboptimal response to treatment occurs, if patient is being intensively treated for &gt;5 days within 4 weeks of the last infusion, or at the following intervals [WFH guidelines (Srivastava 2013)]: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children: Screen for inhibitors every 5 exposure days until 20 exposure days, every 10 exposure days between 21-50 exposure days, and at a minimum of twice a year until 150 exposure days is reached.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults (with &gt;150 exposure days apart from a 6-12 monthly review): Screen for inhibitors when suboptimal response occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23324428\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Average normal factor IX levels are 50% to 150%; patients with severe hemophilia B will have levels &lt;1%, often undetectable. Moderate forms of the disease have levels of 1% to 5% while some mild cases may have 5% to 49% of normal factor IX. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265581\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Replaces deficient clotting factor IX. Hemophilia B, or Christmas disease, is an X-linked inherited disorder of blood coagulation characterized by insufficient or abnormal synthesis of the clotting protein factor IX. Factor IX is a vitamin K-dependent coagulation factor which is synthesized in the liver. Factor IX is activated by factor XIa in the intrinsic coagulation pathway. Activated factor IX (IXa), in combination with factor VII:C activates factor X to Xa, resulting ultimately in the conversion of prothrombin to thrombin and the formation of a fibrin clot. The infusion of exogenous factor IX to replace the deficiency present in hemophilia B temporarily restores hemostasis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265654\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">Half-life elimination: IX component: ~21 to 25 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23324584\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">In absence of inhibitors, 1 unit/kg factor IX human administered will increase plasma factor IX level by 1 unit/dL [WFH guidelines (Srivastava, 2013)].  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570473\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (AlphaNine SD Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 unit (Price provided is per AHF Unit): $1.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Mononine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.61</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059525\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aimafix (TH);</li>\n      <li>Alphanine SD (AE, HK, SG, TH, TW);</li>\n      <li>Bebulin Team 4 (RU);</li>\n      <li>Berinin P (CO);</li>\n      <li>Betafact (IL, LB);</li>\n      <li>Facnyne (KR);</li>\n      <li>Haemonine (GB);</li>\n      <li>Haemosolvex (ZA);</li>\n      <li>Immunine (DE, EE, KW, SE, TH);</li>\n      <li>MonoFIX-VF (AU, NZ);</li>\n      <li>Mononine (CZ, DE, ES, FR, GB, GR, IE, NL, SE, SI, SK);</li>\n      <li>Nonafact (AT, BE, BG, CZ, DK, EE, GR, HR, HU, IE, IT, LT, MT, NL, PL, RO, RU, SE, SK, TR);</li>\n      <li>Octafix (FR);</li>\n      <li>Octanine (MY);</li>\n      <li>Octanine F (AE, CR, DO, GT, HN, NI, PA, SA, SV, UY);</li>\n      <li>Profilnine SD (AE, MY, PH, SG, TH);</li>\n      <li>Replenine VF (IL, MY);</li>\n      <li>Replenine-VF (KW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Batorova A, Martinowitz U. Continuous infusion of coagulation factors. <i>Haemophilia</i>. 2002;8(3):170-177.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/12010406/pubmed\" target=\"_blank\" id=\"12010406\">12010406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chi C, Kadir RA. Inherited bleeding disorders in pregnancy. <i>Best Pract Res Clin Obstet Gynaecol</i>. 2012;26(1):103-117.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/22101176/pubmed\" target=\"_blank\" id=\"22101176\">22101176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoots WK, Leissinger C, Stabler S, et al. Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B. <i>Haemophilia</i>. 2003;9(2):164-172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/12614367/pubmed\" target=\"_blank\" id=\"12614367\">12614367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. <i>Haemophilia</i>. 2009;15(5):990-1005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/19298378/pubmed\" target=\"_blank\" id=\"19298378\">19298378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee CA, Chi C, Pavord SR, et al. The obstetric and gynaecological management of women with inherited bleeding disorders-review with guidelines produced by a Taskforce of UK Haemophilia Centre Doctors' Organization. <i>Haemophilia</i>. 2006;12(4):301-336.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/16834731/pubmed\" target=\"_blank\" id=\"16834731\">16834731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mononine (coagulation factor IX [human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morfini M. Secondary prophylaxis with factor IX concentrates: continuous infusion. <i>Blood Transfus</i>. 2008;6(Suppl 2):21&ndash;25. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/19105506/pubmed\" target=\"_blank\" id=\"19105506\">19105506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poon MC, Card R. Hemophilia management in transfusion medicine. <i>Transfus Apher Sci</i>. 2012;46(3):299-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/22503305/pubmed\" target=\"_blank\" id=\"22503305\">22503305</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. <i>Haemophilia</i>. 1995;1(Suppl 1):8-13.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. <i>Haemophilia</i>. 2013;19(1):e1-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-pediatric-drug-information/abstract-text/22776238/pubmed\" target=\"_blank\" id=\"22776238\">22776238</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 93440 Version 52.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F16264034\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F16264035\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F23324420\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F23324583\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F23324425\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F16321198\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F16264037\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25573583\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F23324426\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F16265579\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F23324421\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F16264032\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F16265559\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F16264049\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F16264050\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25820027\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F16369064\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F16369062\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F16264047\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F16264048\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F23324427\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F23324428\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F16265581\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F16265654\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F23324584\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570473\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059525\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/93440|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=factor-ix-human-plasma-derived-drug-information\" class=\"drug drug_general\">Factor IX, human plasma-derived: Drug information</a></li><li><a href=\"topic.htm?path=factor-ix-human-plasma-derived-patient-drug-information\" class=\"drug drug_patient\">Factor IX, human plasma-derived: Patient drug information</a></li></ul></div></div>","javascript":null}